Stability of alkoxycarbonylamidine prodrugs

Pharmaceutical Research

Volumn 15, Issue 3, 1998, Pages 434-441

  Shahrokh, Zahra ^a   Lee, Eric ^a   Olivero, Alan G ^a   Matamores, Regina A ^a   Robarge, Kirk D ^a   Lee, Arthur ^a   Weise, Kenneth J ^a   Blackburn, Brent K ^a   Powell, Michael F ^a  

^a GENENTECH INC   (United States)

Author keywords

Alkoxycarbonylamidine; Ester; GPII(b)III(a); Peptidomimetic stability; pH rate profile; Prodrug

Indexed keywords

AMIDINE; ESTER; PRODRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG DETERMINATION; DRUG SOLUBILITY; DRUG STABILITY; IN VITRO STUDY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTITION COEFFICIENT; PH; PKA; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

AMIDINES; BENZODIAZEPINES; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; KINETICS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRODRUGS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031900489     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011928415808     Document Type: Article

References (34)

1. H. Buundgaard. The double prodrug concept and its applications. Adv. Drug Delivery Rev. 3:39-65 (1989).
2. N. Bodor and J. J. Kaminski. Prodrugs and site-specific chemical delivery systems. In: Allen, ed. Annual Reports in Medicinal Chemistry, Academic Press. New York, 1987, Vol. 22, pp. 303-313.
3. D. Shan, M. G. Nicolaou, R. T. Borchardt, and B. Wang. Prodrug strategies based on intramolecular cyclization reactions. J. Pharm. Sci. 86:765-7 (1997).
4. R. J. Jones and N. Bischoberger. Minireview: nucleotide prodrugs. Antiviral Res. 27:1-17 (1995).
5. S. H. Yalkowsky, A. A. Sinkula, and S. C. Valvani. Physical Chemical Properties of Drugs. Marcel Dekker Inc., New York, 1980.
6. J. B. Dressman, P. Bass, W. A. Ritschel, D. R. Friend, A. Rubinstein, and E. Ziv. Gastrointestinal parameters that influence oral medications. J. Pharm. Sci. 82:857-872 (1993).
7. J. Blanchard. Gastrointestinal absorption. II. Formulation factors affecting drug bioavailability. Amer. J. Pharm. Sci. Supp. Publ. Health 150:132-151 (1978).
8. G. M. Pauletti, S. Gangwar, G. T. Knipp, M. M. Nerurkar, F. W. Okumu, K. Tamura, T. J. Siahaan, and R. T. Borchardt. Structural requirements for intestinal absorption of peptide drugs. J. Controlled Release 41:3-17 (1996)
9. J. Alexander, D. S. Bindra, D. Glass, M. A. Holahan, M. L. Renyer, G. S. Rork, G. R. Sitko, M. T. Stranieri, R. F. Stupimdki, and H. Veerapanane. Investigation of (Oxodioxylenyl)methyl carbamates as nonchiral bioreversible prodrug moieties for chiral amines. J. Med. Chem. 39:480-6 (1996).
10. B. A. Boucher. Fosphenytoin: A novel phenytoin prodrug. Pharmacotherapy 16:771-91 (1996).
11. E. Rouslahti and M. D. Pierschbacher. New perspectives in cell adhesion: RGD and integrins. Science 238:491-497 (1987).
12. T. Yasuda, H. K. Gold, C. Kohmura, et al. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. Arteroscl. Thromb. 13:738-747 (1993).
13. B. K. Blackburn and T. R. Gadek. Glycoprotein IIbIIIa antagonists. Annual Reports in Medicinal Chemistry. 28:79-88 (1993).
14. R. S. McDowell, B. K. Blackburn, T. R. Gadek, et al. From peptide to non-peptide. 2. The de Novo design of potent, non-peptidal inhibots of platelet aggregation based on a benzodiazepinedione scaffold. J. Am. Chem. Soc. 116:5077-5083 (1994).
15. The EPIC Investigators. Use of a monoclonal antibody direct-edagainst the platelet glycoprotein IIbIIIa in high-risk coronary angioplasty. New Engl. J. Med. 330:956-1007 (1994).
16. T. Weller, L. Alig, M. Beresini M, et al. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J. Med. Chem. 39:3139-3147 (1996).
17. L. W. Dirtert and T. Higuchi. Rates of hydrolysis of carbamate and carbonate esters in alkaline solution. J. Pharm. Sci. 52:852-857 (1963).
18. A. F. Hegarty and L. N. Frost. Elimination-addition mechanism for the hydrolysis of carbamates. Trapping of an isocyanate intermediate by an o-amino-group. J. Chem. Soc. Perkin Trans II: 1719-1728 (1973).
19. A. F. Hegarty, L. N. Frost, J. H. Coy. The question of amide group participation in carbamate hydrolysis. J. Org. Chem. 39:1089-1093 (1974).
20. T. Vontor, J. Socha. and M. Vecera. Kinetics and mechanism of hydrolysis of 1-Naphthyl N-Methyl-and N,N-Dimethylcarbamates. Collection Czechoslov. Chem. Commun. 37:2183-2196 (1972).
21. T. Vontor and M. Vecera. Kinetics and mechanism of hydrolysis of substituted phenyl carbamates. Collection Czechoslov. Chem. Commun. 38:516-522 (1973).
22. G. M. Loudon. Mechanistic interpretation of pH-rate profiles. J. Chem. Educ. 68:973-84 (1991).
23. M. F. Powell, A. Becker, A. Magill. Nonsteroidal anti-psoriatic prodrugs: Hydrolysis and aminolysis of naphthyl esters in aqueous solution. Int. J. Pharmaceutics 35:61-71 (1987).
24. H. Bundgaard, E. Falch, C. Larsen, G. L. Mosher, and T. J. Mikkelson. Pilocarpine prodrugs. II. Synthesis, stability, bioconversion, and physicochemical properties of sequentially labile pilocarpine acid diesters. J. Pharm. Sci. 75:775-783 (1986).
25. C. Bamford and C. Typer. Chemical Kinetics. Elsevier, New York, 1977, p.16.
26. S. Budavari, M. J. O'Neil, A. Smith, P. E. Heckelman, and J. F. Kinnery. The Merck Index. Whitehouse Station, NJ: Merck & Co., Inc., 1996.
27. B. LaDu. Plasma esterase activity and the metabolism of drugs with ester groups. Ann. N. Y. Acad. Sci. 179:684-694 (1993).
28. F. W. Williams. Clinical significance of esterases in man. Clin. Pharmacokin. 10:392-403 (1985).
29. J. C. Pekas. Intestinal hydrolysis, metabolism and transport of a pesticidal carbamate in pH 6.5 medium. Toxicol. Appl. Pharmacol. 23:62-70 (1972).
30. M. Inoue, M. Morikawa, M. Tsuboi, and M. Sugiura. Species difference and characterization of intestinal esterase on the hydrolyzing activity of ester-type drugs. Japan J. Pharmacol. 29:9-16 (1979).
31. L. W. Brown and A. A. Forist. In vitro and in vivo hydrolysis of 4-benzoylphenyl N-methylcarbamate. J. Pharm. Sci. 62:145-146 (1973).
32. K. T. Hansen, P. Faarup, and H. Bundgaard. Carbamate ester prodrugs of dopaminergic compounds: Synthesis, stability, and bioconversion. J. Pharm. Sci. 80:793-798 (1991).
33. J. Alexander, R. A. Fromtling, J. A. Bland, B. A. Pelak, and E. C. Gilfillan. (Acyloxy)alkyl carbamate prodrugs of norfloxacin. J. Med. Chem. 34:78-81 (1991).
34. A. G. Olivero, B. K. Blackburn, K. D. Roburge, R. A. Matamoros, A. Lee, K. Weese, J. P. Burnier, S. Bunting, K. C. Refino, D. Wu, M. T. Lipari, C. Pater, G. G. Deguzman, T. F. Zioncheck, T. Weller, and B. Stainer. Design, synthesis and evaluation of oral GP IIB/IIIA antagonists: A prodrug approach. 212th Am. Chem. Soc. Annual Meeting Abstracts 130a, 1996.